Companies
Novo Nordisk raises outlook as Wegovy pill drives sales beat
Novo Nordisk raised its 2026 outlook after demand for its Wegovy pill helped third-quarter sales top forecasts. Rival Eli Lilly closed at its highest price of the past year.
Quick Read
- Novo Nordisk raised its 2026 outlook after third-quarter sales of $11.90 billion topped the $11.39 billion analysts had estimated.
- The Wegovy pill led obesity drug sales higher, but diabetes sales declined.
- Eli Lilly, which sells a competing pill, closed at a 52-week high on Wednesday.
- Lilly's gain added only a small amount to a broad fund spread across the largest U.S. companies.
What did Novo Nordisk report?
Novo Nordisk raised its full-year outlook for 2026 after third-quarter sales came in ahead of forecasts, the company reported.
Why it matters: Sales reached $11.90 billion, above the $11.39 billion Wall Street analysts had estimated. That average analyst forecast, called the consensus, is the bar a result gets measured against.
By the numbers: Weight-loss drugs did the lifting. Obesity sales climbed 22% once currency swings are stripped out, with the Wegovy pill in the lead. Diabetes sales went the other way and declined.
How is Novo holding up against Eli Lilly?
Eli Lilly (NYSE: LLY) has launched a competing weight-loss pill. In an interview with Reuters, Novo's chief executive, Mike Doustdar, said Novo had kept its position since that launch.
Lilly shares rose 0.6% on Wednesday to close at $1,417.99, a new 52-week high, meaning the highest price of the past year. The gain added $8.1 billion to Lilly's market value, which stands at $1.3 trillion.
That rise was smaller than the move in health care stocks as a group. The health care sector fund (XLV) rose 3.1% on the day.
What does Lilly's move mean for a broad index fund?
Lilly makes up 1.5% of the combined value of the 500 largest U.S. companies. Its gain added $9 to $100,000 spread across those companies by size.
That was a sliver of the day. An S&P 500 index fund added $1,580 on the same $100,000.
What is still unresolved?
The question is whether Wegovy pill sales keep growing now that Lilly sells a rival pill. Novo's next quarterly sales report would show whether its lead holds.
The raised outlook leans on the obesity business, since diabetes sales slipped in the quarter. A slowdown in pill demand could leave less room to make up that decline.
For readers
What it could mean for you: If you own Novo Nordisk or Eli Lilly shares directly, this pill rivalry reaches you in full, with nothing else in your portfolio to cushion it. Novo's quarter shows its Wegovy pill can carry sales even while diabetes revenue slips. Lilly's stock may react to each new sign of how its own pill competes against Wegovy. A future sales update could show patients shifting from one pill to the other. If so, the company losing ground could see its shares move far more than a broad fund that holds them alongside other companies.
Questions and answers
Why did Novo Nordisk raise its 2026 outlook?
Third-quarter sales beat analyst estimates, driven by demand for obesity drugs led by the Wegovy pill. Obesity sales climbed 22% excluding currency swings, the company reported.
Did Novo Nordisk's diabetes sales grow?
No. Diabetes sales declined in the third quarter, so the obesity business carried the result.
How did Eli Lilly stock react to Novo's results?
Lilly shares rose 0.6% on Wednesday and closed at their highest price of the past year. Novo's chief executive told Reuters the company had kept its position since Lilly launched its rival pill.
The numbers
| Eli Lilly (LLY) price | $1,417.99 |
|---|---|
| Eli Lilly (LLY) change | +0.61% |
| Eli Lilly (LLY) market value | $1.3 trillion |
| Eli Lilly (LLY) 52-week high | $1,417.99 |
| S&P 500 change | +1.58% |
| 10-year Treasury yield | 4.90% |
Wednesday’s close
Companies in this story
Share this story
Not investment advice.
